Aesthetic treatments During Menopause

Patients in the perimenopausal and menopausal years often arrive at consultation with a sense that the face has changed in ways that previous interventions did not anticipate. Skin that was reliable for decades has lost its bounce. Volume that sat where it should has begun to redistribute. Lines that softened with previous neuromodulator treatment now seem to persist between cycles. The conversation about what is happening, and what aesthetic treatment can and cannot do about it, deserves more honesty than the consultation usually receives.

What hormonal change is doing to the face

The decline in oestrogen across the perimenopausal and menopausal years has measurable effects on facial skin and soft tissue. Dermal collagen synthesis falls. Skin thickness decreases. Hyaluronic acid content in the dermis reduces. Fat pad behaviour changes, with deep medial cheek atrophy often becoming more visible. Bone density changes contribute to the slow remodelling of the facial skeleton that has been quietly underway for years. None of these changes is unique to menopause, but the rate of change accelerates during this period.

The published literature on dermal collagen change in postmenopausal patients is consistent: most studies estimate a loss of around two percent of dermal collagen per year in the years immediately following menopause, with the decline slowing over time. Skin thickness studies show a similar pattern. The visible result is the change in skin quality that patients describe as the face suddenly catching up with them.

What injectable treatment can address in this context

Conservative neuromodulator treatment continues to soften dynamic expression lines in the same regions and with the same dose ranges as in pre menopausal patients. The mechanism is the same. The duration is sometimes slightly shorter because the post menopausal face metabolises the product fractionally faster, but the difference is rarely clinically significant. Patients who had stable maintenance rhythms before menopause usually continue with similar rhythms after.

Conservative facial volume treatment can address some of the volume changes that emerge with menopause, particularly the deep medial cheek atrophy that contributes to the flatter mid face appearance and the deeper tear trough shadowing that often accompanies it. The principles of anatomy led, conservative dosing apply. The clinical reality is that volume treatment can soften the visible signs of certain volume changes without addressing the underlying hormonal change driving them, and the conversation needs to name that limit clearly.

What injectable treatment cannot address

Skin quality changes (loss of dermal collagen, reduced skin thickness, the matte texture that replaces the reflectivity of younger skin) are not addressed by aesthetic treatment. These are dermal and epidermal changes that respond to skin care interventions, medical grade topical strategies, dermatological care, and where appropriate, hormone replacement therapy under specialist supervision. Aesthetic treatment practitioners do not provide these interventions and we say so directly when the conversation indicates that skin is the dominant concern.

The fundamental limit is honest: injectables address muscular activity and volume. They do not address the substrate of the skin. A patient whose primary concern is skin quality will be disappointed by an injectable plan that does not also address the skin separately. Naming this distinction at consultation is part of the model.

The role of hormone replacement therapy in this conversation

Hormone replacement therapy is a medical decision that sits with the patient and their general practitioner, gynaecologist or specialist physician. We do not prescribe HRT, we do not recommend for or against it, and we do not consider it part of cosmetic practice. The relevant point at injectable consultation is that patients who are taking HRT may have somewhat different skin and tissue profiles than patients of the same age who are not, and the planning conversation accommodates that.

For patients who are weighing HRT separately, the conversation about aesthetic treatments is independent of that decision. Treatment can be appropriate with or without HRT, and the planning is anatomy led rather than hormonally driven.

Conservative dosing principles in the menopausal patient

The conservative dosing principles that apply across the practice apply with particular relevance in this patient population. Smaller starting doses with structured two week reviews. Adjustment based on actual response rather than on the maximum dose for the region. Staging of treatment across multiple sessions where appropriate. The pace of change is gradual.

The reasoning specific to this patient group is that the face is genuinely changing month to month for some patients in active perimenopause, and a single session full dose treatment can produce a result that does not match the face six months later. The structured review interval gives the opportunity to recalibrate against actual current anatomy rather than against the anatomy at the moment of the first treatment.

What the consultation usually covers

For patients in this period, the consultation tends to be longer than average because the conversation about what is changing, why it is changing and what can and cannot be done about it benefits from time. We work through the visible changes the patient is concerned about. We map them to the underlying contributors (skin quality, fat pad atrophy, bone remodelling, muscular dynamics, gravitational descent). We identify which contributors are within injectable scope and which are not. The plan that emerges from this conversation is honest about both.

Patients sometimes leave the consultation with no immediate treatment plan, having decided that the priority is to address skin quality first through other modalities and to revisit the injectable conversation in twelve months. This is a clinically appropriate outcome and is encouraged where it fits the situation.

AHPRA September 2025 considerations

The AHPRA guidelines for nonsurgical cosmetic procedures that came into force in September 2025 require an in person or video consultation with the prescribing practitioner each time a aesthetic treatment is prescribed. Suitability assessment must explicitly address motivations and expectations, which in this patient population sometimes includes a discussion about the broader context of how the patient is experiencing midlife change and whether injectable treatment is the appropriate response to what they are noticing.

The framework also reinforces the importance of explicit acknowledgment of treatment limits, which in this context means naming clearly what aesthetic treatments can and cannot do for the changes the patient is experiencing.

Why we do not name the prescription product

Australian regulation prohibits the advertising of Schedule 4 prescription medicines to the public. That includes the brand names, abbreviations and hashtags associated with aesthetic treatment products. We can talk in clinical detail about the mechanism, dose ranges, response profile and safety considerations. We do not name brands or otherwise identify products to the public, because the law explicitly prohibits us from doing so.

What we do not claim

Several claims commonly made about aesthetic treatments in the menopausal patient do not survive clinical scrutiny and we do not make them. The first is that injectable treatment will reverse the visible signs of menopausal facial change. It can soften some specific signs; it cannot reverse the underlying biological process. The second is that more aggressive treatment in this period will hold off ageing more effectively. It will not, and aggressive treatment in this patient group is more likely to produce visible disproportion than effective rejuvenation. The third is that injectable treatment is a substitute for skin quality interventions or for medical management of menopausal symptoms. It is not.

On safety and preexisting conditions

The patient population in this period is more likely to have begun managing one or more chronic medical conditions (osteoporosis, hypertension, thyroid dysfunction, diabetes, cardiovascular disease, autoimmune disease) and to be on chronic medication. The relevant medical history is reviewed at consultation. Most chronic conditions and their typical medications do not contraindicate aesthetic treatment, but specific situations (anticoagulation, immunosuppression, neuromuscular disease, recent significant infection) require explicit discussion and sometimes deferral.

Patients are encouraged to bring an current medication list to consultation, including any over the counter supplements or herbal products that may affect bleeding, healing or interaction with the prescription products being considered.

Working with Corey

Corey Anderson is the only practitioner at Core Aesthetics. Registered with the Nursing and Midwifery Board of Australia since January 1996 (AHPRA NMW0001047575), Corey runs a one practitioner, low volume clinic in Oakleigh. For patients in the perimenopausal and menopausal years, the continuity of clinician across years matters because the face is changing through this period and the treatment plan benefits from being built and adjusted by someone who has watched the change unfold rather than meeting the patient at a single point in time.

Patients see Corey at every visit. Treatment notes carry the dose, placement, response and the broader trajectory forward across years.

Cost framing

Pricing is straightforward. Each treatment is priced on the actual product and time involved, quoted in writing as part of the consultation. There is no surge pricing, no time limited promotional pricing and no loyalty pricing. Patients receive a written treatment plan that includes the realistic anticipated frequency of maintenance and the cumulative cost across the first twelve months.

Booking a consultation

Consultations are individually scheduled and the first appointment is a clinical assessment, with no obligation to proceed in the same session. For patients in this period, the consultation tends to run longer because of the substantive nature of the conversation about what is changing and what can be done about it. Results vary between individuals. The plan is built around the specific anatomy, hormonal context and goals of the person in front of us.

Core Aesthetics operates from 12A Atherton Road, Oakleigh, in Melbourne south east. Booking is direct online or by contacting the clinic.

A note on the patient experience over years

For patients who are followed across the perimenopausal and early postmenopausal years, the treatment plan often shifts in emphasis. Early in the period, the conversation may be predominantly about preserving expression and softening dynamic lines. Later, the conversation often shifts towards conservative volume support in regions where the deep medial cheek atrophy has begun to read on the face. Even later, the conversation often shifts again towards maintenance of what has been built rather than towards new intervention. The trajectory is gradual and the plan adjusts at each cycle to match where the face actually is rather than where it was six months earlier.

Patients who experience this kind of unhurried, year by year refinement often describe it as one of the more useful aspects of the consultation based model. The alternative (the high throughput model where the same plan is delivered at each visit regardless of changing context) does not fit the realities of facial change in this period.

On expectation setting

The most reliable predictor of patient satisfaction with aesthetic treatment in this period is the alignment between what was discussed at consultation and what the patient experiences after. Patients who arrived with realistic expectations of conservative softening and volume support tend to be satisfied. Patients who arrived expecting a more dramatic outcome and were not gently guided towards a more realistic expectation at consultation tend to be disappointed. The honest framing at the start of the conversation is one of the most important parts of the consultation, particularly in this patient group.

On co management with primary care

Many patients in this period are simultaneously navigating conversations with their general practitioner about menopausal symptom management, with their dentist about ongoing oral health, and sometimes with a dermatologist about skin care. Aesthetic treatment practice fits within this broader picture rather than competing with it. We are happy to share clinical notes with another treating practitioner where the patient consents, and patients sometimes find that having all of the relevant clinicians aware of the broader context produces better coordinated care than treating each domain in isolation.

For patients without an established general practice relationship, the consultation may include a recommendation to establish one before further injectable work, particularly where the medical history suggests that another assessment would be useful before proceeding.

Coordination across clinicians is part of how good practice runs in this period; siloed care tends to produce inconsistent advice that the patient has to reconcile alone.

The patient who is being managed coherently across their healthcare contacts tends to make better aligned decisions about cosmetic intervention than the patient who is navigating each conversation alone.

That coordination is part of the broader principle of consultation based practice in this period of life, where small interventions sit within a much larger health context that deserves attention.

This integrated framing is one of the central commitments of the C.O.R.E. Method approach in patients moving through this period.

The conversation rewards patience, in other words, far more than it rewards aggressive intervention.

On the broader experience of midlife facial change

The cultural conversation about menopause and the face has shifted in recent years towards more honest acknowledgment of what is happening biologically and what the realistic options are. The previous frame, which positioned cosmetic intervention as the answer to a problem that was often poorly defined, has been replaced in better practice by a more nuanced conversation about specific contributors, specific options, and the personal decision of how a patient wants to approach this period of life.

Aesthetic treatment can be one component of that approach for some patients. For others it is not the right priority. For most it is most useful as part of a broader plan that includes attention to skin quality, sleep, sun protection, lifestyle, and the medical management of menopausal symptoms where that is appropriate. The consultation is the place to think through where injectable treatment fits in the patient broader picture.